Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Julphar
McKesson
Dow
Citi
Baxter
Deloitte
Harvard Business School
Fish and Richardson

Generated: June 25, 2018

DrugPatentWatch Database Preview

Amag Pharma Usa Company Profile

« Back to Dashboard

What is the competitive landscape for AMAG PHARMA USA, and when can generic versions of AMAG PHARMA USA drugs launch?

AMAG PHARMA USA has one approved drug.

There are eight US patents protecting AMAG PHARMA USA drugs.

There are forty-one patent family members on AMAG PHARMA USA drugs in twelve countries.

Summary for Amag Pharma Usa
International Patents:41
US Patents:8
Tradenames:3
Ingredients:1
NDAs:1

Drugs and US Patents for Amag Pharma Usa

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amag Pharma Usa MAKENA (AUTOINJECTOR) hydroxyprogesterone caproate SOLUTION;SUBCUTANEOUS 021945-004 Feb 14, 2018 RX Yes Yes 9,789,257 ➤ Sign Up Y ➤ Sign Up
Amag Pharma Usa MAKENA (AUTOINJECTOR) hydroxyprogesterone caproate SOLUTION;SUBCUTANEOUS 021945-004 Feb 14, 2018 RX Yes Yes RE44846 ➤ Sign Up Y ➤ Sign Up
Amag Pharma Usa MAKENA PRESERVATIVE FREE hydroxyprogesterone caproate SOLUTION;INTRAMUSCULAR 021945-002 Feb 19, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up
Amag Pharma Usa MAKENA (AUTOINJECTOR) hydroxyprogesterone caproate SOLUTION;SUBCUTANEOUS 021945-004 Feb 14, 2018 RX Yes Yes 9,180,259 ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Amag Pharma Usa

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,446,195 Injection device with cammed ram assembly ➤ Sign Up
RE44847 Needle assisted jet injector ➤ Sign Up
6,428,528 Needle assisted jet injector ➤ Sign Up
8,496,619 Injection device with cammed ram assembly ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Queensland Health
Teva
Julphar
US Department of Justice
Harvard Business School
Chinese Patent Office
Dow
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.